| Chronotherapy with modified-release prednisone in patients with rheumatoid arthritis. | |
| | |
MedLine Citation:
|
PMID: 22288450 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Glucocorticoids are indispensable for the treatment of systemic inflammatory diseases such as rheumatoid arthritis (RA), though their beneficial effects have to be balanced with potential complications arising from high doses, prolonged use or dose splitting. A glucocorticoid formulation (modified-release prednisone) has been developed to be taken in accordance with biological rhythms (chronotherapy). Morning symptoms of RA are caused by elevated nocturnal levels of proinflammatory cytokines, particularly IL-6. Endogenous cortisol levels may be insufficient to counter the inflammatory effects of IL-6. The early morning rise in cortisol can be supplemented with exogenous glucocorticoid replacement therapy if this is given as the recently developed chronotherapy formulation. There is no adverse impact of modified-release prednisone on the hypothalamic-pituitary-adrenal (HPA) axis; indeed, there might be evidence of a beneficial effect on HPA axis function. This review summarizes the development of modified-release prednisone, pharmacokinetic characteristics and clinical experience in patients with RA. |
| | |
Authors:
|
Rieke Alten |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert review of clinical immunology Volume: 8 ISSN: 1744-8409 ISO Abbreviation: Expert Rev Clin Immunol Publication Date: 2012 Feb |
Date Detail:
|
Created Date: 2012-01-31 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101271248 Medline TA: Expert Rev Clin Immunol Country: England |
Other Details:
|
Languages: eng Pagination: 123-33 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine II, Rheumatology, Clinical Immunology & Osteology, Schlosspark-Klinik Teaching Hospital Charité University Medicine Berlin, Heubnerweg 2, 14059 Berlin, Germany. rieke.alten@schlosspark-klinik.de. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pharmacological Modulation of microparticles Release: New Strategies for the Management of Atherothr...
Next Document: Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.